Shilpa Medicare Ltd

Shilpa Medicare Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.25, indicating a relatively low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.46, suggesting it can cover its short-term obligations but with limited buffer. However, the company's free cash flow is negative at -600,021,000 INR, which may signal pressure on liquidity if capital expenditures remain high. Profitability metrics show a return on equity of 3.3% and a return on assets of 2.36%, both below the typical thresholds for high-performing pharmaceutical firms. These figures suggest that the company is generating modest returns relative to its equity and asset base. The operating margin, calculated as operating income of 1,631,306,000 INR on revenue of 12,864,140,000 INR, is 12.7%, which is in line with the industry median for pharmaceutical firms. The company's revenue is concentrated in its domestic market, with no disclosed international revenue segments. This lack of geographic diversification may expose the company to regulatory and economic risks specific to India. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or therapeutic areas. Looking ahead, the company's revenue is projected to grow, though the exact rate is not disclosed. The capital expenditure of -2,436,340,000 INR indicates a significant investment in infrastructure or expansion, which may support future growth. However, the negative free cash flow suggests that the company is currently reinvesting heavily rather than generating surplus cash for dividends or debt reduction. The risk assessment highlights a key liquidity flag: the company's net cash position is negative after subtracting total debt. This could indicate a potential challenge in maintaining liquidity if cash flow from operations does not improve. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. The company's capital structure remains stable, with no significant dilution expected in the next 12 months. Recent filings and transcripts do not disclose any material events that would significantly alter the company's financial or operational outlook. The company continues to operate within its core pharmaceutical business, with no indication of strategic shifts or major acquisitions.